![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Active Filter(s):
Details:
At the Day 3 primary endpoint, SAGE-217/BIIB125 (Zuranolone), investigational oral neuroactive steroid GABA-A receptor-positive allosteric modulator, 50 mg co-initiated with a standard of care antidepressant showed a statistically significant reduction in depressive symptoms.
Lead Product(s): Zuranolone,Escitalopram Oxalate
Therapeutic Area: Psychiatry/Psychology Product Name: SAGE-217
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Biogen
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 16, 2022